Historical Valuation
China SXT Pharmaceuticals Inc (SXTC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of China SXT Pharmaceuticals Inc (SXTC) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：4.03
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
China SXT Pharmaceuticals Inc (SXTC) has a current Price-to-Book (P/B) ratio of 9.98. Compared to its 3-year average P/B ratio of 0.72 , the current P/B ratio is approximately 1286.16% higher. Relative to its 5-year average P/B ratio of 0.82, the current P/B ratio is about 1121.46% higher. China SXT Pharmaceuticals Inc (SXTC) has a Forward Free Cash Flow (FCF) yield of approximately -1.36%. Compared to its 3-year average FCF yield of -66.27%, the current FCF yield is approximately -97.95% lower. Relative to its 5-year average FCF yield of -40.92% , the current FCF yield is about -96.68% lower.
P/B
Median3y
0.72
Median5y
0.82
FCF Yield
Median3y
-66.27
Median5y
-40.92
Competitors Valuation Multiple
AI Analysis for SXTC
The average P/S ratio for SXTC competitors is 3.07, providing a benchmark for relative valuation. China SXT Pharmaceuticals Inc Corp (SXTC.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SXTC
1Y
3Y
5Y
Market capitalization of SXTC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SXTC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SXTC currently overvalued or undervalued?
China SXT Pharmaceuticals Inc (SXTC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of China SXT Pharmaceuticals Inc (SXTC) is between to according to relative valuation methord.
What is China SXT Pharmaceuticals Inc (SXTC) fair value?
SXTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of China SXT Pharmaceuticals Inc (SXTC) is between to according to relative valuation methord.
How does SXTC's valuation metrics compare to the industry average?
The average P/S ratio for SXTC's competitors is 3.07, providing a benchmark for relative valuation. China SXT Pharmaceuticals Inc Corp (SXTC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for China SXT Pharmaceuticals Inc (SXTC) as of Jan 09 2026?
As of Jan 09 2026, China SXT Pharmaceuticals Inc (SXTC) has a P/B ratio of 9.98. This indicates that the market values SXTC at 9.98 times its book value.
What is the current FCF Yield for China SXT Pharmaceuticals Inc (SXTC) as of Jan 09 2026?
As of Jan 09 2026, China SXT Pharmaceuticals Inc (SXTC) has a FCF Yield of -1.36%. This means that for every dollar of China SXT Pharmaceuticals Inc’s market capitalization, the company generates -1.36 cents in free cash flow.
What is the current Forward P/E ratio for China SXT Pharmaceuticals Inc (SXTC) as of Jan 09 2026?
As of Jan 09 2026, China SXT Pharmaceuticals Inc (SXTC) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of China SXT Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for China SXT Pharmaceuticals Inc (SXTC) as of Jan 09 2026?
As of Jan 09 2026, China SXT Pharmaceuticals Inc (SXTC) has a Forward P/S ratio of 0.00. This means the market is valuing SXTC at $0.00 for every dollar of expected revenue over the next 12 months.